{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T06:09:00Z","timestamp":1789625340097,"version":"build-2803163510"},"reference-count":36,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background &amp; objectives:<\/jats:title>\n                    <jats:p>Lymphatic filariasis is targeted for elimination in India through mass drug administration (MDA) with diethylcarbamazine (DEC) combined with albendazole (ABZ). To assess the coverage, compliance and causes for non-compliance towards MDA in an endemic district of Uttar Pradesh (U.P.), north India.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A cross-sectional coverage evaluation survey was conducted in 24 rural and 6 urban clusters of Ghazipur district in eastern U.P. using multi-stage random sampling technique with probability proportional to estimated size (PPES). Data was collected in a semi-structured Performa from all the individuals in the selected households by interview technique. Bivariate analysis was performed to identify the factors associated with non-consumption of MDA drugs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>A total of 1422 individuals were surveyed from 30 randomly selected subunits of which 1401 (98.5%) were eligible for MDA at the time of the round. Majority of the participants were in the age-group of 15\u201359 years (67.0%) and were males (53.3%). The overall coverage of MDA (both drugs) among the eligible population in Ghazipur district was 58.5%. Compliance among those who had received both the drugs was 61.6% with effective coverage of 36.0%. The coverage was significantly higher in rural areas compared to the urban clusters (p&lt;0.0001). The most common reason quoted for not consuming drugs was fear of side effects (34.9%). However, the incidence of adverse events among those who consumed the drugs was only 2.5%. None of the socio-demographic variables showed a significant association with the compliance to the drugs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interpretation &amp; conclusion:<\/jats:title>\n                    <jats:p>Coverage and compliance of MDA in Ghazipur district of U.P., India was found to be below satisfactory levels. Targeted Information Education and Communication (IEC) campaigns focusing on the safety of drugs and the necessity of MDA, and mass mobilization with effective monitoring and supervision is the need of the hour for effective coverage of MDA Programme.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/0972-9062.374034","type":"journal-article","created":{"date-parts":[[2023,4,10]],"date-time":"2023-04-10T10:01:41Z","timestamp":1681120901000},"page":"307-316","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":8,"title":["Coverage and compliance of mass drug administration (MDA) programme for elimination of lymphatic filariasis in an endemic district of eastern Uttar Pradesh, India"],"prefix":"10.4103","volume":"60","author":[{"given":"Abu","family":"Bashar","sequence":"first","affiliation":[{"name":"Department of Community and Family Medicine, All India Institute of Medical Sciences, Gorakhpur, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanket V.","family":"Nandekar","sequence":"additional","affiliation":[{"name":"Department of Community Medicine, Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prerna","family":"Shrivastava","sequence":"additional","affiliation":[{"name":"Department of Community Medicine, Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi Nandini","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Community Medicine, Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pushkar","family":"Srikrishnan","sequence":"additional","affiliation":[{"name":"Department of Community Medicine, Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,10,6]]},"reference":[{"key":"R1-20240830","first-page":"1731","article-title":"Using knowledge, attitudes and practice (KAP) surveys on lymphatic filariasis to prepare a health promotion campaign for mass drug administration in Alor District, Indonesia.","volume":"11","author":"Krentel","year":"2006","journal-title":"Trop Med IntHealth"},{"key":"R3-20240830","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1590\/S0102-311X1997000300030","article-title":"Lymphatic Filariasis: a potentially eradicable disease.","volume":"13","author":"Dreyer","year":"1997","journal-title":"Cadernos de Sa\u00fade P\u00fablica"},{"issue":"3","key":"R7-20240830","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.puhe.2011.11.015","article-title":"The global burden of neglected tropical diseases.","volume":"126","author":"Fenwick","year":"2012","journal-title":"Public Health"},{"issue":"3","key":"R10-20240830","doi-asserted-by":"crossref","first-page":"232","DOI":"10.4103\/0022-3859.68650","article-title":"Lymphatic filariasis in India: epidemiology and control measures.","volume":"56","author":"Raju","year":"2010","journal-title":"J Postgrad Med"},{"issue":"6","key":"R11-20240830","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S0169-4758(00)01643-4","article-title":"The economic burden of lymphatic filariasis in India.","volume":"16","author":"Ramaiah","year":"2000","journal-title":"Parasitol Today"},{"key":"R12-20240830","first-page":"1","article-title":"Recommendations of the international task force for disease eradication.","volume":"42","year":"1993","journal-title":"MMWR"},{"key":"R14-20240830","first-page":"491","article-title":"Strategies and tools for the control elimination of Lymphatic filariasis.","volume":"75","author":"Otteson","year":"1997","journal-title":"Bull World Health Organ"},{"key":"R15-20240830","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/j.1365-3156.1997.tb00157.x","article-title":"Ivermectin for the chemotherapy of bancroftian filariasis: a meta analysis of the effect of single treatment.","volume":"2","author":"Cao","year":"1997","journal-title":"Trop Med Int Heath"},{"key":"R16-20240830","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/S0035-9203(98)90972-5","article-title":"Efficacy of single dose combinations of Ivermectin, Albendazole and DEC for the treatment of Bancroftian Filariasis.","volume":"92","author":"Ismail","year":"1997","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"2","key":"R18-20240830","doi-asserted-by":"crossref","first-page":"138","DOI":"10.2471\/BLT.06.029389","article-title":"Vector control complements mass drug administration against bancroftian filariasis in Tirukoilur, India.","volume":"85","author":"Sunish","year":"2007","journal-title":"Bull World Health Organ"},{"issue":"10-12","key":"R19-20240830","first-page":"34","article-title":"Integrating MDA with vector control for elimination of filariasis.","volume":"38","year":"2008","journal-title":"ICMR Bulletin"},{"key":"R20-20240830","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1475-2883-5-10","article-title":"The argument for integrating vector control with multiple drug administration campaigns to ensure elimination of lymphatic filariasis.","volume":"5","author":"Burkot","year":"2006","journal-title":"Filaria J"},{"issue":"9","key":"R23-20240830","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1093\/trstmh\/tru057","article-title":"Coverage of, and compliance with, mass drug administration under the programme to eliminate lymphatic filariasis in India: a systematic review.","volume":"108","author":"Babu","year":"2014","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"R24-20240830","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1046\/j.1365-3156.2001.00682.x","article-title":"The impact of 34 years of massive DEC chemotherapy on Wuchereria bancrofti infection and transmission: the Maupiti cohort","volume":"6","author":"Esterre","year":"2001","journal-title":"Trop Med Int Health"},{"key":"R28-20240830","article-title":"Probability Proportional to Size (PPS) Sampling","author":"Skinner","year":"2016","journal-title":"Wiley Online Library"},{"issue":"1","key":"R29-20240830","doi-asserted-by":"crossref","first-page":"1","DOI":"10.9734\/IJTDH\/2016\/21628","article-title":"Filarial Elimination in India Missing Its Deadline\u2013 Evidence from a Cross Sectional Study of Four Districts of Uttar Pradesh.","volume":"13","author":"Singh","year":"2015","journal-title":"International Journal of Tropical Disease & Health"},{"issue":"3","key":"R30-20240830","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.18203\/2394-6040.ijcmph20210843","article-title":"A study on coverage and compliance of mass drug administration for lymphatic filariasis in Prayagraj District, Uttar Pradesh, India.","volume":"8","author":"Ram","year":"2021","journal-title":"Int J Community Med Public Health"},{"issue":"9","key":"R31-20240830","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.4103\/jfmpc.jfmpc_503_19","article-title":"Coverage of mass drug administration for elimination of lymphatic filariasis in urban Nagpur, Central India: A mixed method study.","volume":"8","author":"Banerjee","year":"2019","journal-title":"J Family Med Prim Care"},{"issue":"1","key":"R32-20240830","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.inhe.2010.12.001","article-title":"Coverage and compliance to mass drug administration for lymphatic filariasis elimination in a district of Kerala, India.","volume":"3","author":"Nujum","year":"2011","journal-title":"International Health"},{"issue":"2","key":"R33-20240830","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3329\/jhpn.v31i2.16380","article-title":"Coverage and awareness of and compliance with mass drug administration for elimination of lymphatic filariasis in Burdwan District, West Bengal, India.","volume":"31","author":"Roy","year":"2013","journal-title":"J Health Popul Nutr"},{"issue":"1","key":"R34-20240830","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.cegh.2019.04.013","article-title":"Mass drug administration programme against lymphatic filariasis-an evaluation of coverage and compliance in a northern Karnataka district, India.","volume":"8","author":"Kulkarni","year":"2020","journal-title":"Clinical Epidemiology and Global Health"},{"key":"R35-20240830","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/2049-9957-3-31","article-title":"Mass drug administration for lymphatic filariasis elimination in a coastal state of India: a study on barriers to coverage and compliance.","volume":"3","author":"Hussain","year":"2014","journal-title":"Infect Dis Poverty"},{"key":"R36-20240830","doi-asserted-by":"crossref","first-page":"137","DOI":"10.4103\/ijhas.IJHAS_23_17","article-title":"Coverage of mass drug administration and status of mass drug administration program in Bankura district of West Bengal, India","volume":"6","author":"Haldar","year":"2017","journal-title":"Int J Health Allied Sci"},{"issue":"1","key":"R37-20240830","doi-asserted-by":"crossref","first-page":"42","DOI":"10.4103\/2229-5070.149921","article-title":"Is the coverage of mass-drug-administration adequate for elimination of Bancroftian filariasis? An experience from West Bengal, India.","volume":"5","author":"Haldar","year":"2015","journal-title":"Trop Parasitol"},{"issue":"1","key":"R38-20240830","doi-asserted-by":"crossref","first-page":"67","DOI":"10.4103\/2229-5070.113917","article-title":"Mass drug administration for elimination of lymphatic filariasis: Recent experiences from a district of West Bengal, India.","volume":"3","author":"Ghosh","year":"2013","journal-title":"Trop Parasitol"},{"issue":"4","key":"R39-20240830","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/S2222-1808(12)60063-2","article-title":"Coverage and compliance MDA programme for lymphatic filariasis in Bidar district, Karnataka, India.","volume":"2","author":"Koradhanyamath","year":"2012","journal-title":"Asian Pacific Journal of Tropical Disease"},{"key":"R40-20240830","doi-asserted-by":"crossref","first-page":"219","DOI":"10.4103\/0970-0218.103468","article-title":"Elimination of Lymphatic Filariasis: Mass Drug Administration in Endemic Areas of (Bidar District) Karnataka-2008.","volume":"37","author":"Ranganath","year":"2012","journal-title":"Indian J Community Med"},{"issue":"3","key":"R41-20240830","doi-asserted-by":"crossref","first-page":"287","DOI":"10.47203\/IJCH.2018.v30i03.017","article-title":"Mass Drug Administration (MDA) for Elimination of Lymphatic Filariasis: Experiences from Nayagarh District of Odisha, India.","volume":"30","author":"Bhatia","year":"2018","journal-title":"Indian J Community Health"},{"key":"R42-20240830","doi-asserted-by":"crossref","first-page":"4311","DOI":"10.18203\/2394-6040.ijcmph20183965","article-title":"Coverage and compliance towards mass drug administration programme against lymphatic filariasis in Vijayapura (Bijapur) district, Karnataka, India.","volume":"5","author":"Kulkarni","year":"2018","journal-title":"Int J Community Med Public Health"},{"key":"R43-20240830","first-page":"6","article-title":"Coverage and Compliance of Mass Drug Administration for Elimination of Lymphatic Filariasis in Bijapur District, Karnataka.","volume":"2","author":"Waseem","year":"2015","journal-title":"Annals of Community Health"},{"key":"R44-20240830","doi-asserted-by":"crossref","first-page":"e728","DOI":"10.1371\/journal.pntd.0000728","article-title":"Increasing compliance with mass drug administration programs for lymphatic filariasis in India through Education and Lymphedema Management Programs","volume":"4","author":"Cantey","year":"2010","journal-title":"PLoS Negl Trop Dis"},{"key":"R45-20240830","first-page":"1","article-title":"Lymphatic filariasis. Monitoring and epidemiological assessment of the programme to eliminate lymphatic filariasis at implementation unit level","volume":"50","year":"2005","journal-title":"WHO\/CDS\/CPE\/CEE\/"},{"issue":"4","key":"R46-20240830","first-page":"313","article-title":"Strengthening of mass drug administration implementation is required to eliminate lymphatic filariasis from India: an evaluation study.","volume":"45","author":"Lahariya","year":"2008","journal-title":"J Vector Borne Dis"},{"issue":"1","key":"R47-20240830","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4103\/0972-9062.203157","article-title":"How endemic countries can accelerate lymphatic filariasis elimination? An analytical review to identify strategic and programmatic interventions.","volume":"48","author":"Lahariya","year":"2011","journal-title":"J Vector Borne Dis"},{"issue":"6","key":"R48-20240830","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s13312-018-1341-1","article-title":"\u2018Ayushman Bharat\u2019 Program and Universal Health Coverage in India.","volume":"55","author":"Lahariya","year":"2018","journal-title":"Indian Pediatr"},{"issue":"11","key":"R49-20240830","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1007\/s12098-020-03359-z","article-title":"Health & Wellness Centers to Strengthen Primary Health Care in India: Concept, Progress and Ways Forward.","volume":"87","author":"Lahariya","year":"2020","journal-title":"Indian J Pediatr"}],"updated-by":[{"DOI":"10.4103\/0972-9062.392443","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,12,29]],"date-time":"2023-12-29T00:00:00Z","timestamp":1703808000000}}],"container-title":["Journal of Vector Borne Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/0972-9062.374034","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:14:23Z","timestamp":1787166863000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/0972-9062.374034"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.4103\/0972-9062.374034","relation":{},"ISSN":["0972-9062"],"issn-type":[{"value":"0972-9062","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"2022-07-19","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-06","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}